4/A//SEC Filing
BLECH ISAAC 4/A
Accession 0000899243-19-009670
CIK 0001501697other
Filed
Apr 1, 8:00 PM ET
Accepted
Apr 2, 8:02 PM ET
Size
8.8 KB
Accession
0000899243-19-009670
Insider Transaction Report
Form 4/AAmended
BLECH ISAAC
Director
Transactions
- Award
Stock Option (right to buy)
2019-03-13+70,796→ 70,796 totalExercise: $6.84Exp: 2025-12-14→ Common Stock (70,796 underlying) - Award
Stock Option (right to buy)
2019-03-13+6,854→ 6,854 totalExercise: $18.66Exp: 2029-03-13→ Common Stock (6,854 underlying)
Footnotes (3)
- [F1]Fully vested.
- [F2]Reflects the Reporting Person's stock option to acquire 744,967 shares of X4 common stock for $0.65 per share that was assumed by the Issuer in the merger of Artemis AC Corp., a wholly-owned subsidiary of the Issuer, with and into X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) ("X4") on March 13, 2019 (the "Merger").
- [F3]33.3333% of the shares subject to the option shall vest on March 13, 2020, with the remainder vesting in equal monthly installments of 2.7777% of the shares subject to the option until the 36-month anniversary of the date of the award, subject to the Reporting Person continuing to provide service through each such date. This amendment is being filed solely to report this additional stock option grant, which was granted automatically on March 13, 2019 pursuant to the Issuer's Director Compensation Policy upon such Reporting Person's election to the Board of Directors of the Issuer in connection with the closing of the Merger.
Documents
Issuer
X4 Pharmaceuticals, Inc
CIK 0001501697
Entity typeother
Related Parties
1- filerCIK 0000905536
Filing Metadata
- Form type
- 4/A
- Filed
- Apr 1, 8:00 PM ET
- Accepted
- Apr 2, 8:02 PM ET
- Size
- 8.8 KB